Cancer stem cell quiescence and plasticity as major challenges in cancer therapy

Stem Cells International

Volumn 2016, Issue , 2016, Pages

  Chen, Wanyin ^a   Dong, Jihu ^a   Haiech, Jacques ^a   Kilhoffer, Marie Claude ^a   Zeniou, Maria ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTIGEN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2;

APOPTOSIS; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CELL FUNCTION; CELL PLASTICITY; CELL QUIESCENCE; CELL SELF-RENEWAL; CELL SURFACE; CELLULAR PARAMETERS; DNA DAMAGE; DNA REPAIR; DRUG TRANSPORT; ENRICHMENT CULTURE; HUMAN; IN VIVO STUDY; METASTASIS; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84978765993     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2016/1740936     Document Type: Review

References (166)

1. D. Bonnet and J. E. Dick, "Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell, " Nature Medicine, vol. 3, no. 7, pp. 730-737, 1997.
2. M. Shackleton, E. Quintana, E. R. Fearon, and S. J. Morrison, "Heterogeneity in cancer: cancer stem cells versus clonal evolution, " Cell, vol. 138, no. 5, pp. 822-829, 2009.
3. F. Islam, B. Qiao, R. A. Smith, V. Gopalan, and A. K.-Y. Lam, "Cancer stem cell: fundamental experimental pathological concepts and updates, " Experimental and Molecular Pathology, vol. 98, no. 2, pp. 184-191, 2015.
4. J. E. Visvader, "Cells of origin in cancer, " Nature, vol. 469, no. 7330, pp. 314-322, 2011.
5. J. E. Visvader and G. J. Lindeman, "Cancer stem cells in solid tumours: accumulating evidence and unresolved questions, " Nature Reviews Cancer, vol. 8, no. 10, pp. 755-768, 2008.
6. C. L. Chaffer, I. Brueckmann, C. Scheel, et al., "Normal and neoplastic nonstem cells can spontaneously convert to a stemlike state, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 19, pp. 7950-7955, 2011.
7. C. L. Chaffer, N. D. Marjanovic, T. Lee, et al., "XPoisedchromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity, " Cell, vol. 154, no. 1, pp. X61-74, 2013.
8. D. Iliopoulos, H. A. Hirsch, G. Wang, and K. Struhl, "Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 4, pp. 1397-1402, 2011.
9. L. Fulawka, P. Donizy, and A. Halon, "Cancer stem cells-the current status of an old concept: literature review and clinical approaches, " Biological Research, vol. 47, no. 1, article 66, 2014.
10. M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison, and M. F. Clarke, "Prospective identification of tumorigenic breast cancer cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 3983-3988, 2003.
11. C. Ginestier, M. H. Hur, E. Charafe-Jauffret, et al., "ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome, " Cell Stem Cell, vol. 1, no. 5, pp. 555-567, 2007.
12. R. Galli, E. Binda, U. Orfanelli, et al., "Isolation and characterization of tumorigenic, stem-like neural precursors fromhuman glioblastoma, " Cancer Research, vol. 64, no. 19, pp. 7011-7021, 2004.
13. H. D. Hemmati, I. Nakano, J. A. Lazareff, et al., "Cancerous stem cells can arise from pediatric brain tumors, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 25, pp. 15178-15183, 2003.
14. S. K. Singh, I. D. Clarke, M. Terasaki, et al., "Identification of a cancer stem cell in human brain tumors, " Cancer Research, vol. 63, no. 18, pp. 5821-5828, 2003.
15. S. K. Singh, C. Hawkins, I. D. Clarke, et al., "Identification of human brain tumour initiating cells, " Nature, vol. 432, no. 7015, pp. 396-401, 2004.
16. X. Yuan, J. Curtin, Y. Xiong, et al., "Isolation of cancer stem cells from adult glioblastoma multiforme, " Oncogene, vol. 23, no. 58, pp. 9392-9400, 2004.
17. P. C. Hermann, S. L. Huber, T. Herrler, et al., "Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer, " Cell Stem Cell, vol. 1, no. 3, pp. 313-323, 2007.
18. C. Li, D. G. Heidt, P. Dalerba, et al., "Identification of pancreatic cancer stem cells, " Cancer Research, vol. 67, no. 3, pp. 1030-1037, 2007.
19. P. Dalerba, S. J. Dylla, I.-K. Park, et al., "Phenotypic characterization of human colorectal cancer stem cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 24, pp. 10158-10163, 2007.
20. C. A. O'Brien, A. Pollett, S. Gallinger, and J. E. Dick, "A human colon cancer cell capable of initiating tumour growth in immunodeficient mice, " Nature, vol. 445, no. 7123, pp. 106-110, 2007.
21. L. Ricci-Vitiani, D. G. Lombardi, E. Pilozzi, et al., "Identification and expansion of human colon-cancer-initiating cells, " Nature, vol. 445, no. 7123, pp. 111-115, 2007.
22. M. E. Prince, R. Sivanandan, A. Kaczorowski, et al., "Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 3, pp. 973-978, 2007.
23. Z. F. Yang, D. W. Ho, M. N. Ng, et al., "Significance of CD90+ cancer stem cells in human liver cancer, " Cancer Cell, vol. 13, no. 2, pp. 153-166, 2008.
24. A. Eramo, F. Lotti, G. Sette, et al., "Identification and expansion of the tumorigenic lung cancer stem cell population, " Cell Death and Differentiation, vol. 15, no. 3, pp. 504-514, 2008.
25. C. F. Bender Kim, E. L. Jackson, A. E. Woolfenden, et al., "Identification of bronchioalveolar stem cells in normal lung and lung cancer, " Cell, vol. 121, no. 6, pp. 823-835, 2005.
26. A. T. Collins, P. A. Berry, C. Hyde, M. J. Stower, and N. J. Maitland, "Prospective identification of tumorigenic prostate cancer stem cells, " Cancer Research, vol. 65, no. 23, pp. 10946-10951, 2005.
27. K. S. Chan, I. Espinosa, M. Chao, et al., "Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 33, pp. 14016-14021, 2009.
28. P. P. Szotek, R. Pieretti-Vanmarcke, P. T. Masiakos, et al., "Ovarian cancer side population defines cells with stem celllike characteristics andMullerian Inhibiting Substance responsiveness, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 30, pp. 11154-11159, 2006.
29. S. Zhang, C. Balch, M. W. Chan, et al., "Identification and characterization of ovarian cancer-initiating cells from primary human tumors, " Cancer Research, vol. 68, no. 11, pp. 4311-4320, 2008.
30. D. Fang, T. K. Nguyen, K. Leishear, et al., "A tumorigenic subpopulation with stem cell properties in melanomas, " Cancer Research, vol. 65, no. 20, pp. 9328-9337, 2005.
31. E. Quintana, M. Shackleton, M. S. Sabel, D. R. Fullen, T. M. Johnson, and S. J. Morrison, "Efficient tumour formation by single human melanoma cells, " Nature, vol. 456, no. 7222, pp. 593-598, 2008.
32. T. Schatton, G. F. Murphy, N. Y. Frank, et al., "Identification of cells initiating human melanomas, " Nature, vol. 451, no. 7176, pp. 345-349, 2008.
33. M. Salerno, S. Avnet, G. Bonuccelli, et al., "Sphere-forming cell subsets with cancer stem cell properties in human musculoskeletal sarcomas, " International Journal of Oncology, vol. 43, no. 1, pp. 95-102, 2013.
34. T. Lapidot, C. Sirard, J. Vormoor, et al., "A cell initiating human acute myeloid leukaemia after transplantation into SCID mice, " Nature, vol. 367, no. 6464, pp. 645-648, 1994.
35. T. Baba, P. A. Convery, N. Matsumura, et al., "Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells, " Oncogene, vol. 28, no. 2, pp. 209-218, 2009.
36. E. Monzani, F. Facchetti, E. Galmozzi, et al., "Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential, " European Journal of Cancer, vol. 43, no. 5, pp. 935-946, 2007.
37. B. Greve, R. Kelsch, K. Spaniol, H. T. Eich, and M. Gotte, "Flow cytometry in cancer stem cell analysis and separation, " Cytometry Part A, vol. 81, no. 4, pp. 284-293, 2012.
38. H. Liu, L. Lv, and K. Yang, "Chemotherapy targeting cancer stem cells, " American Journal of Cancer Research, vol. 5, no. 3, pp. 880-893, 2015.
39. J. P. Medema, "Cancer stem cells: the challenges ahead, " Nature Cell Biology, vol. 15, no. 4, pp. 338-344, 2013.
40. C. Hadjimichael, K. Chanoumidou, N. Papadopoulou, P. Arampatzi, J. Papamatheakis, and A. Kretsovali, "Common stemness regulators of embryonic and cancer stem cells, " World Journal of Stem Cells, vol. 7, no. 9, pp. 1150-1184, 2015.
41. A. Liu, X. Yu, and S. Liu, "Pluripotency transcription factors and cancer stem cells: small genes make a big difference, " Chinese Journal of Cancer, vol. 32, no. 9, pp. 483-487, 2013.
42. S. Lemma, S. Avnet, M. Salerno, T. Chano, N. Baldini, and J. S. Castresana, "Identification and validation of housekeeping genes for gene expression analysis of cancer stem cells, " PLoS ONE, vol. 11, no. 2, Article IDe0149481, 2016.
43. M. Feve, J.-M. Saliou, M. Zeniou, et al., "Comparative expression study of the endo-G protein coupled receptor (GPCR) repertoire in human glioblastoma cancer stem-like cells, U87-MG cells and non malignant cells of neural origin unveils new potential therapeutic targets, " PLoS ONE, vol. 9, no. 3, Article ID e91519, 2014.
44. M. Zeniou, M. Feve, S. Mameri, et al., "Chemical library screening and structure-function relationship studies identify bisacodyl as a potent and selective cytotoxic agent towards quiescent human glioblastoma tumor stem-like cells, " PLoS ONE, vol. 10, no. 8, Article IDe0134793, 2015.
45. H. Clevers, "The cancer stem cell: premises, promises and challenges, " Nature Medicine, vol. 17, no. 3, pp. 313-319, 2011.
46. A. B. Hjelmeland and J. N. Rich, "The quest for self-identity: not all cancer stem cells are the same, " Clinical Cancer Research, vol. 18, no. 13, pp. 3495-3498, 2012.
47. M. Boesch, D. Wolf, and S. Sopper, "Optimized stem cell detection using the DyeCycle-triggered side population phenotype, " Stem Cells International, vol. 2016, Article ID 1652389, 14 pages, 2016.
48. A. Golebiewska, N. H. C. Brons, R. Bjerkvig, and S. P. Niclou, "Critical appraisal of the side population assay in stem cell and cancer stem cell research, " Cell Stem Cell, vol. 8, no. 2, pp. 136-147, 2011.
49. V. Richard, M. G. Nair, T. R. Santhosh Kumar, and M. R. Pillai, "Side population cells as prototype of chemoresistant, tumorinitiating cells, " BioMed Research International, vol. 2013, Article ID 517237, 8 pages, 2013.
50. S. Bandhavkar, "Cancer stem cells: a metastasizing menace!, " Cancer Medicine, vol. 5, no. 4, pp. 649-655, 2016.
51. A. Borah, S. Raveendran, A. Rochani, T. Maekawa, and D. S. Kumar, "Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy, " Oncogenesis, vol. 4, no. 11, article e177, 2015.
52. M. Katoh, "Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis, " StemCell Reviews, vol. 3, no. 1, pp. 30-38, 2007.
53. P. A. Sotiropoulou, M. S. Christodoulou, A. Silvani, C. Herold-Mende, and D. Passarella, "Chemical approaches to targeting drug resistance in cancer stem cells, " Drug Discovery Today, vol. 19, no. 10, pp. 1547-1562, 2014.
54. N. Takebe, L. Miele, P. J. Harris, et al., "Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update, " Nature Reviews Clinical Oncology, vol. 12, no. 8, pp. 445-464, 2015.
55. B. Ramaswamy, Y. Lu, K.-Y. Teng, et al., "Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway, " Cancer Research, vol. 72, no. 19, pp. 5048-5059, 2012.
56. R. L. Yauch, G. J. P. Dijkgraaf, B. Alicke, et al., "Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma, " Science, vol. 326, no. 5952, pp. 572-574, 2009.
57. A. E. Sloan, C. J. Nock, X. B. Ye, et al., "Targeting gliomainitiating cells in GBM: ABTC-0904, a randomized phase 0/II study targeting the SonicHedgehog-signaling pathway, " Journal of Clinical Oncology, vol. 32, abstract 2026, 2014, Proceedings of the 2014 ASCO Annual Meeting.
58. A. N. Hata, J. A. Engelman, and A. C. Faber, "The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics, " Cancer Discovery, vol. 5, no. 5, pp. 475-487, 2015.
59. D. Capper, T. Gaiser, C. Hartmann, et al., "Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation, " Acta Neuropathologica, vol. 117, no. 4, pp. 445-456, 2009.
60. F. Jin, L. Zhao, H.-Y. Zhao, et al., "Comparison between cells and cancer stem-like cells isolated from glioblastoma and astrocytoma on expression of anti-apoptotic and multidrug resistance-associated protein genes, " Neuroscience, vol. 154, no. 2, pp. 541-550, 2008.
61. G. P. Dunn, M. L. Rinne, J. Wykosky, et al., "Emerging insights into themolecular and cellular basis of glioblastoma, "Genes and Development, vol. 26, no. 8, pp. 756-784, 2012.
62. F. B. Furnari, T. Fenton, R. M. Bachoo, et al., "Malignant astrocytic glioma: genetics, biology, and paths to treatment, " Genes & Development, vol. 21, no. 21, pp. 2683-2710, 2007.
63. K. E. Tagscherer, A. Fassl, B. Campos, et al., "Apoptosisbased treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins, " Oncogene, vol. 27, no. 52, pp. 6646-6656, 2008.
64. L. Piggott, N. Omidvar, S. Marti Perez, R. French, M. Eberl, and R. W. Clarkson, "Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL, " Breast Cancer Research, vol. 13, no. 5, article R88, 2011.
65. Y.-P. Yang, Y. Chien, G.-Y. Chiou, et al., "Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethaneshort branch PEI, " Biomaterials, vol. 33, no. 5, pp. 1462-1476, 2012.
66. Q. E. Wang, "DNA damage responses in cancer stem cells: implications for cancer therapeutic strategies, " World Journal of Biological Chemistry, vol. 6, no. 3, pp. 57-64, 2015.
67. S. Bao, Q. Wu, R. E. McLendon, et al., "Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, " Nature, vol. 444, no. 7120, pp. 756-760, 2006.
68. V. A. Venkatesha, L. A. Parsels, J. D. Parsels, et al., "Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition, " Neoplasia, vol. 14, no. 6, pp. 519-525, 2012.
69. S. Facchino, M. Abdouh, W. Chatoo, and G. Bernier, "BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery, " Journal of Neuroscience, vol. 30, no. 30, pp. 10096-10111, 2010.
70. Y.-C. Chen, C.-J. Chang, H.-S. Hsu, et al., "Inhibition of tumorigenicity and enhancement of radiochemosensitivity in head and neck squamous cell cancer-derived ALDH1-positive cells by knockdown of Bmi-1, " Oral Oncology, vol. 46, no. 3, pp. 158-165, 2010.
71. G. Liu, X. Yuan, Z. Zeng, et al., "Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma, " Molecular Cancer, vol. 5, article 67, 2006.
72. L. A. Mathews, S. M. Cabarcas, E. M. Hurt, X. Zhang, E. M. Jaffee, and W. L. Farrar, "Increased expression of DNA repair genes in invasive human pancreatic cancer cells, " Pancreas, vol. 40, no. 5, pp. 730-739, 2011.
73. C.-H. Chang, M. Zhang, K. Rajapakshe, et al., "Mammary stem cells and tumor-initiating cells are more resistant to apoptosis and exhibit increased DNA repair activity in response to DNA damage, " Stem Cell Reports, vol. 5, no. 3, pp. 378-391, 2015.
74. E. Singer, J. Judkins, N. Salomonis, et al., "Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma, " Cell Death and Disease, vol. 6, no. 1, Article ID e1601, 2015.
75. L. Chang, P. Graham, J. Hao, et al., "Cancer stem cells and signaling pathways in radioresistance, " Oncotarget, vol. 7, no. 10, pp. 11002-11017, 2016.
76. S. Ding, C. Li, N. Cheng, X. Cui, X. Xu, and G. Zhou, "Redox regulation in cancer stem cells, " OxidativeMedicine and Cellular Longevity, vol. 2015, Article ID 750798, 11 pages, 2015.
77. V. J. Bhagwandin, J. M. Bishop, W. E. Wright, and J. W. Shay, "The metastatic potential and chemoresistance of human pancreatic cancer stem cells, " PLoS ONE, vol. 11, no. 2, Article ID e0148807, 2016.
78. T. Chiba, K. Kita, Y.-W. Zheng, et al., "Side population purified from hepatocellular carcinoma cells harbors cancer stem celllike properties, " Hepatology, vol. 44, no. 1, pp. 240-251, 2006.
79. J. Liu, N. Chi, J. Y. Zhang, W. Zhu, Y. S. Bian, and H. G. Chen, "Isolation and characterization of cancer stem cells from medulloblastoma, " Genetics andMolecular Research, vol. 14, no. 2, pp. 3355-3361, 2015.
80. C. Di and Y. Zhao, "Multiple drug resistance due to resistance to stem cells and stem cell treatment progress in cancer, " Experimental and Therapeutic Medicine, vol. 9, no. 2, pp. 289-293, 2015.
81. D. L. Dragu, L. G. Necula, C. Bleotu, C. C. Diaconu, and M. Chivu-Economescu, "Therapies targeting cancer stem cells: current trends and future challenges, " World Journal of Stem Cells, vol. 7, no. 9, pp. 1185-1201, 2015.
82. S. Karthikeyan and S. L. Hoti, "Development of fourth generation ABC inhibitors from natural products: a novel approach to overcome cancer multidrug resistance, " Anti-Cancer Agents in Medicinal Chemistry, vol. 15, no. 5, pp. 605-615, 2015.
83. D. R. Pattabiraman and R. A. Weinberg, "Tackling the cancer stem cells-what challenges do they pose?" Nature Reviews Drug Discovery, vol. 13, no. 7, pp. 497-512, 2014.
84. S. G. M. Piccirillo, B. A. Reynolds, N. Zanetti, et al., "Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells, " Nature, vol. 444, no. 7120, pp. 761-765, 2006.
85. J. Lee, M. J. Son, K. Woolard, et al., "Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells, " Cancer Cell, vol. 13, no. 1, pp. 69-80, 2008.
86. V. Balasubramaniyan, B. Vaillant, S. Wang, et al., "Aberrantmesenchymal differentiation of glioma stem-like cells: implications for therapeutic targeting, " Oncotarget, vol. 6, no. 31, pp. 31007-31017, 2015.
87. T. H. Cheung and T. A. Rando, "Molecular regulation of stem cell quiescence, " Nature Reviews Molecular Cell Biology, vol. 14, no. 6, pp. 329-340, 2013.
88. B. Martynoga, J. L. Mateo, B. Zhou, et al., "Epigenomic enhancer annotation reveals a key role for NFIX in neural stem cell quiescence, " Genes and Development, vol. 27, no. 16, pp. 1769-1786, 2013.
89. J.-H. Paik, Z. Ding, R. Narurkar, et al., "FoxOs cooperatively regulate diverse pathways governing neural stemcell homeostasis, " Cell Stem Cell, vol. 5, no. 5, pp. 540-553, 2009.
90. J. R. Valcourt, J. M. S. Lemons, E. M. Haley, M. Kojima, O. O. Demuren, and H. A. Coller, "Staying alive: metabolic adaptations to quiescence, " Cell Cycle, vol. 11, no. 9, pp. 1680-1696, 2012.
91. S. H. Wang and S. Lin, "Tumor dormancy: potential therapeutic target in tumor recurrence and metastasis prevention, " Experimental Hematology & Oncology, vol. 2, no. 1, article 29, 2013.
92. M. S. Sosa, P. Bragado, and J. A. Aguirre-Ghiso, "Mechanisms of disseminated cancer cell dormancy: an awakening field, " Nature Reviews Cancer, vol. 14, no. 9, pp. 611-622, 2014.
93. J. L. Dembinski and S. Krauss, "Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma, " Clinical and Experimental Metastasis, vol. 26, no. 7, pp. 611-623, 2009.
94. S. Pece, D. Tosoni, S. Confalonieri, et al., "Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content, " Cell, vol. 140, no. 1, pp. 62-73, 2010.
95. N. Haraguchi, H. Ishii, K. Mimori, et al., "CD13 is a therapeutic target in human liver cancer stem cells, "The Journal of Clinical Investigation, vol. 120, no. 9, pp. 3326-3339, 2010.
96. A. Roesch, M. Fukunaga-Kalabis, E. C. Schmidt, et al., "A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth, " Cell, vol. 141, no. 4, pp. 583-594, 2010.
97. M.-Q. Gao, Y.-P. Choi, S. Kang, J. H. Youn, and N.-H. Cho, "CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells, " Oncogene, vol. 29, no. 18, pp. 2672-2680, 2010.
98. Z. Vincent, K. Urakami, K. Maruyama, K. Yamaguchi, and M. Kusuhara, "CD133-positive cancer stem cells from Colo205 human colon adenocarcinoma cell line show resistance to chemotherapy and display a specific metabolomic profile, " Genes & Cancer, vol. 5, no. 7-8, pp. 250-260, 2014.
99. L. P. Deleyrolle, A. Harding, K. Cato, et al., "Evidence for labelretaining tumour-initiating cells in human glioblastoma, " Brain, vol. 134, no. 5, pp. 1331-1343, 2011.
100. J. Chen, Y. Li, T.-S. Yu, et al., "A restricted cell population propagates glioblastoma growth after chemotherapy, " Nature, vol. 488, no. 7412, pp. 522-526, 2012.
101. A. P. Patel, I. Tirosh, J. J. Trombetta, et al., "Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma, " Science, vol. 344, no. 6190, pp. 1396-1401, 2014.
102. A. Ishii, T. Kimura, H. Sadahiro, et al., "Histological characterization of the tumorigenic Peri-Necrotic Niche harboring quiescent stem-like tumor cells in glioblastoma, " PLoSONE, vol. 11, no. 1, Article ID e0147366, 2016.
103. S. Takeishi, A. Matsumoto, I. Onoyama, K. Naka, A. Hirao, and K. I. Nakayama, "Ablation of Fbxw7 eliminates leukemiainitiating cells by preventing quiescence, " Cancer Cell, vol. 23, no. 3, pp. 347-361, 2013.
104. Y. Saito, N. Uchida, S. Tanaka, et al., "Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML, " Nature Biotechnology, vol. 28, no. 3, pp. 275-280, 2010.
105. A. P. Adam, A. George, D. Schewe, et al., "Computational identification of a p38 SAPK-regulated transcription factor network required for tumor cell quiescence, " Cancer Research, vol. 69, no. 14, pp. 5664-5672, 2009.
106. P. Bragado, Y. Estrada, F. Parikh, et al., "TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling, " Nature Cell Biology, vol. 15, no. 11, pp. 1351-1361, 2013.
107. A. Kobayashi, H. Okuda, F. Xing, et al., "Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stemlike cells in bone, " The Journal of Experimental Medicine, vol. 208, no. 13, pp. 2641-2655, 2011.
108. M. C. Cabrera, R. E. Hollingsworth, and E. M. Hurt, "Cancer stem cell plasticity and tumor hierarchy, "World Journal of Stem Cells, vol. 7, no. 1, pp. 27-36, 2015.
109. A. Avgustinova and S. A. Benitah, "The epigenetics of tumour initiation: cancer stem cells and their chromatin, " Current Opinion in Genetics & Development, vol. 36, pp. 8-15, 2016.
110. A. O. Pisco and S. Huang, "Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: what does not kill me strengthens me, " British Journal of Cancer, vol. 112, no. 11, pp. 1725-1732, 2015.
111. E. Quintana, M. Shackleton, H. R. Foster, et al., "Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized, " Cancer Cell, vol. 18, no. 5, pp. 510-523, 2010.
112. M. L. Suva, E. Rheinbay, S. M. Gillespie, et al., "Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells, " Cell, vol. 157, no. 3, pp. 580-594, 2014.
113. N. Oshima, Y. Yamada, S. Nagayama, et al., "Induction of cancer stem cell properties in colon cancer cells by defined factors, " PLoS ONE, vol. 9, no. 7, Article ID e101735, 2014.
114. M. R. Junttila and F. J. de Sauvage, "Influence of tumour microenvironment heterogeneity on therapeutic response, " Nature, vol. 501, no. 7467, pp. 346-354, 2013.
115. L. Lacina, J. Plzak, O. Kodet, et al., "Cancer microenvironment: what can we learn from the stem cell niche, " International Journal of Molecular Sciences, vol. 16, no. 10, pp. 24094-24110, 2015.
116. V. Plaks, N. Kong, and Z. Werb, "Thecancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?" Cell Stem Cell, vol. 16, no. 3, pp. 225-238, 2015.
117. M. A. LaBarge, "The difficulty of targeting cancer stem cell niches, " Clinical Cancer Research, vol. 16, no. 12, pp. 3121-3129, 2010.
118. H. C. Chong, C. K. Tan, R.-L. Huang, and N. S. Tan, "Matricellular proteins: a sticky affair with cancers, " Journal of Oncology, vol. 2012, Article ID 351089, 17 pages, 2012.
119. P. Lu, V. M. Weaver, and Z. Werb, "The extracellular matrix: a dynamic niche in cancer progression, " The Journal of Cell Biology, vol. 196, no. 4, pp. 395-406, 2012.
120. F. M. Watt and W. T. S. Huck, "Role of the extracellularmatrix in regulating stem cell fate, "Nature ReviewsMolecular Cell Biology, vol. 14, no. 8, pp. 467-473, 2013.
121. C. Farace, J. A. Oliver, C. Melguizo, et al., "Microenvironmental modulation of decorin and lumican in temozolomide-resistant glioblastoma and neuroblastoma cancer stem-like cells, " PLoS ONE, vol. 10, no. 7, Article ID e0134111, 2015.
122. E. Fessler, T. Borovski, and J. P. Medema, "Endothelial cells induce cancer stem cell features in differentiated glioblastoma cells via bFGF, " Molecular Cancer, vol. 14, article 157, 2015.
123. A. Singh and J. Settleman, "EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer, " Oncogene, vol. 29, no. 34, pp. 4741-4751, 2010.
124. J. P. Thiery and J. P. Sleeman, "Complex networks orchestrate epithelial-mesenchymal transitions, " Nature Reviews Molecular Cell Biology, vol. 7, no. 2, pp. 131-142, 2006.
125. M. R. Doherty, J. M. Smigiel, D. J. Junk, and M. W. Jackson, "Cancer stem cell plasticity drives therapeutic resistance, " Cancers (Basel), vol. 8, no. 1, p. 8, 2016.
126. S. A. Mani, W. Guo, M.-J. Liao, et al., "The epithelialmesenchymal transition generates cells with properties of stem cells, " Cell, vol. 133, no. 4, pp. 704-715, 2008.
127. A. Mitra, L. Mishra, and S. Li, "EMT, CTCs and CSCs in tumor relapse and drug-resistance, " Oncotarget, vol. 6, no. 13, pp. 10697-10711, 2015.
128. F. Andriani, G. Bertolini, F. Facchinetti, et al., "Conversion to stem-cell state in response to microenvironmental cues is regulated by balance between epithelial and mesenchymal features in lung cancer cells, " Molecular Oncology, vol. 10, no. 2, pp. 253-271, 2016.
129. I. Kryczek, Y. Lin, N. Nagarsheth, et al., "IL-22+CD4+ Tcellspromote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L, " Immunity, vol. 40, no. 5, pp. 772-784, 2014.
130. M. Santisteban, J. M. Reiman, M. K. Asiedu, et al., "Immuneinduced epithelial to mesenchymal transition in vivo generates breast cancer stem cells, " Cancer Research, vol. 69, no. 7, pp. 2887-2895, 2009.
131. S. Hamada, A. Masamune, T. Takikawa, et al., "Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells, " Biochemical and Biophysical Research Communications, vol. 421, no. 2, pp. 349-354, 2012.
132. E. Lonardo, J. Frias-Aldeguer, P. C. Hermann, and C. Heeschen, "Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness, " Cell Cycle, vol. 11, no. 7, pp. 1282-1290, 2012.
133. J. Evans, A. Essex, H. Xin, N. Amitai, L. Brinton, and E. Griner, "Registered report:Wnt activity defines colon cancer stem cells and is regulated by the microenvironment, " eLife, vol. 4, Article ID e07301, 2015.
134. L. Vermeulen, F. De Sousa E Melo, M. van der Heijden, et al., "Wnt activity defines colon cancer stem cells and is regulated by the microenvironment, " Nature Cell Biology, vol. 12, no. 5, pp. 468-476, 2010.
135. J. A. Bertout, S. A. Patel, and M. C. Simon, "The impact of O2 availability on human cancer, " Nature Reviews Cancer, vol. 8, no. 12, pp. 967-975, 2008.
136. N. C. Denko, "Hypoxia, HIF1 and glucose metabolism in the solid tumour, " Nature Reviews Cancer, vol. 8, no. 9, pp. 705-713, 2008.
137. E. Paolicchi, F. Gemignani, M. Krstic-Demonacos, S. Dedhar, L. Mutti, and S. Landi, "Targeting hypoxic response for cancer therapy, " Oncotarget, vol. 7, no. 12, pp. 13464-13478, 2016.
138. B. Philip, K. Ito, R. Moreno-Sanchez, and S. J. Ralph, "HIF expression and the role of hypoxic microenvironments within primary tumours as protective sites driving cancer stem cell renewal and metastatic progression, " Carcinogenesis, vol. 34, no. 8, pp. 1699-1707, 2013.
139. J. M. Heddleston, Z. Li, J. D. Lathia, S. Bao, A. B. Hjelmeland, and J. N. Rich, "Hypoxia inducible factors in cancer stem cells, " British Journal of Cancer, vol. 102, no. 5, pp. 789-795, 2010.
140. Y. Kim, Q. Lin, P. M. Glazer, and Z. Yun, "Hypoxic tumor microenvironment and cancer cell differentiation, " Current Molecular Medicine, vol. 9, no. 4, pp. 425-434, 2009.
141. J. Mathieu, Z. Zhang, W. Zhou, et al., "HIF induces human embryonic stem cell markers in cancer cells, " Cancer Research, vol. 71, no. 13, pp. 4640-4652, 2011.
142. J. M. Heddleston, Z. Li, R. E. McLendon, A. B. Hjelmeland, and J. N. Rich, "The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype, " Cell Cycle, vol. 8, no. 20, pp. 3274-3284, 2009.
143. Z. Li, S. Bao, Q. Wu, et al., "Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells, " Cancer Cell, vol. 15, no. 6, pp. 501-513, 2009.
144. K. Helczynska, A. Kronblad, A. Jogi, et al., "Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ, " Cancer Research, vol. 63, no. 7, pp. 1441-1444, 2003.
145. E. Louie, S. Nik, J.-S. Chen, et al., "Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation, " Breast Cancer Research, vol. 12, no. 6, article R94, 2010.
146. B. Das, R. Tsuchida, D. Malkin, G. Koren, S. Baruchel, and H. Yeger, "Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction, " STEM CELLS, vol. 26, no. 7, pp. 1818-1830, 2008.
147. N. Platet, S. Y. Liu, M. E. Atifi, et al., "Influence of oxygen tension on CD133 phenotype in human glioma cell cultures, " Cancer Letters, vol. 258, no. 2, pp. 286-290, 2007.
148. R. P. Hill, D. T. Marie-Egyptienne, and D. W. Hedley, "Cancer stem cells, hypoxia and metastasis, " Seminars in Radiation Oncology, vol. 19, no. 2, pp. 106-111, 2009.
149. T. van den Beucken, E. Koch, K. Chu, et al., "Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER, " Nature Communications, vol. 5, article 5203, 2014.
150. Y. J. Yang, H. J. Na, M. J. Suh, et al., "Hypoxia induces epithelial-mesenchymal transition in follicular thyroid cancer: involvement of regulation of twist by hypoxia inducible factor-1α, " Yonsei Medical Journal, vol. 56, no. 6, pp. 1503-1514, 2015.
151. J. Guo, B. Wang, Z. Fu, J. Wei, and W. Lu, "Hypoxic microenvironment induces EMT and upgrades stem-like properties of gastric cancer cells, " Technology in Cancer Research & Treatment, vol. 15, no. 1, pp. 60-68, 2016.
152. S. Liu, S. M. Kumar, J. S. Martin, R. Yang, and X. Xu, "Snail1 mediates hypoxia-induced melanoma progression, " The American Journal of Pathology, vol. 179, no. 6, pp. 3020-3031, 2011.
153. J. Chiche, M. C. Brahimi-Horn, and J. Pouyssegur, "Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer, " Journal of Cellular and Molecular Medicine, vol. 14, no. 4, pp. 771-794, 2010.
154. A. B. Hjelmeland, Q. Wu, J. M. Heddleston, et al., "Acidic stress promotes a glioma stem cell phenotype, " Cell Death and Differentiation, vol. 18, no. 5, pp. 829-840, 2011.
155. C. Lagadec, E. Vlashi, L. Della Donna, C. Dekmezian, and F. Pajonk, "Radiation-induced reprogramming of breast cancer cells, " STEM CELLS, vol. 30, no. 5, pp. 833-844, 2012.
156. C. Nor, Z. C. Zhang, K. A. Warner, et al., "Cisplatin inducesBmi and enhances the stem cell fraction in head and neck cancer, " Neoplasia, vol. 16, no. 2, pp. 137-146, 2014.
157. A. Roesch, A. Vultur, I. Bogeski, et al., "Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells, " Cancer Cell, vol. 23, no. 6, pp. 811-825, 2013.
158. C. Denise, P. Paoli, M. Calvani, et al., "5-Fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits, " Oncotarget, vol. 6, no. 39, pp. 41706-41721, 2015.
159. S. Vanharanta and J. Massague, "Origins of metastatic traits, " Cancer Cell, vol. 24, no. 4, pp. 410-421, 2013.
160. L. Wan, K. Pantel, and Y. Kang, "Tumormetastasis:moving new biological insights into the clinic, " Nature Medicine, vol. 19, no. 11, pp. 1450-1464, 2013.
161. S. Kimbung, N. Loman, and I. Hedenfalk, "Clinical andmolecular complexity of breast cancer metastases, " Seminars in Cancer Biology, vol. 35, pp. 85-95, 2015.
162. I. Baccelli, A. Schneeweiss, S. Riethdorf, et al., "Identification of a population of blood circulating tumor cells frombreast cancer patients that initiates metastasis in a xenograft assay, " Nature Biotechnology, vol. 31, no. 6, pp. 539-544, 2013.
163. T. Hiraga, S. Ito, and H. Nakamura, "Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production, " Cancer Research, vol. 73, no. 13, pp. 4112-4122, 2013.
164. C. van den Hoogen, G. van der Horst, H. Cheung, et al., "High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer, " Cancer Research, vol. 70, no. 12, pp. 5163-5173, 2010.
165. D. A. Lawson, N. R. Bhakta, K. Kessenbrock, et al., "Single-cell analysis reveals a stem-cell program in humanmetastatic breast cancer cells, " Nature, vol. 526, no. 7571, pp. 131-135, 2015.
166. I. Malanchi, A. Santamaria-Martinez, E. Susanto, et al., "Interactions between cancer stem cells and their niche govern metastatic colonization, " Nature, vol. 481, no. 7379, pp. 85-91, 2012.